(2024) 10:e25680
(NYSE: HIMS), a large publicly traded company Offers real FDA-approved brand-name medications like Wegovy and Zepbound, not just compounded versions Strong BBB record: A+ accreditation and roughly 3.8/5 across thousands of reviews Well-documented company history dating back to 2017 Hers Cons Mandatory $149/mo membership is billed separately from medication and doesn't guarantee a prescription Cheapest compounded semaglutide tier requires a 12-month prepay Realistic total monthly cost, membership plus medication, commonly runs $298 or more Not available in all 50 states for GLP-1 prescriptions TrimRx vs
Continuous-output operation supports blinder and wash effects
When Eli Lilly designed the Phase 2 clinical trial that put Retatrutide on the map, they tested four different dose groups (1mg, 4mg, 8mg, and 12mg) alongside a placebo group
Recently, Pfizer also successfully secured the ownership of GLP-1 biotechnology company Metsera after a surprise bidding conflict, adding Metseras injectable asset, MET-097i (which is in Phase 2b testing and has the potential for once-a-month dosing), to its portfolio
Lyophilized Powder Research Grade This peptide has been the subject of extensive research for its role in various biological mechanisms
